156 related articles for article (PubMed ID: 31521062)
21. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
22. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
[TBL] [Abstract][Full Text] [Related]
23. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
24. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
Mowla A; Dastgheib SA; Razeghian Jahromi L
Clin Drug Investig; 2016 Jul; 36(7):539-43. PubMed ID: 27071759
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study.
Bilodeau M; Simon T; Beauchamp MH; Lespérance P; Dubreucq S; Dorée JP; Tourjman SV
J Atten Disord; 2014 Feb; 18(2):169-75. PubMed ID: 22582349
[TBL] [Abstract][Full Text] [Related]
27. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
Marchettini P; Wilhelm S; Petto H; Tesfaye S; Tölle T; Bouhassira D; Freynhagen R; Cruccu G; Lledó A; Choy E; Kosek E; Micó JA; Späth M; Skljarevski V; Lenox-Smith A; Perrot S
Eur J Pain; 2016 Mar; 20(3):472-82. PubMed ID: 26311228
[TBL] [Abstract][Full Text] [Related]
28. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
29. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
30. Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Noma H; Furukawa TA; Maruo K; Imai H; Shinohara K; Tanaka S; Ikeda K; Yamawaki S; Cipriani A
J Affect Disord; 2019 May; 250():419-424. PubMed ID: 30878654
[TBL] [Abstract][Full Text] [Related]
31. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.
Kao WT; Chang CL; Lung FW
J Affect Disord; 2018 Oct; 238():597-608. PubMed ID: 29957477
[TBL] [Abstract][Full Text] [Related]
32. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
[TBL] [Abstract][Full Text] [Related]
33. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.
Hellerstein DJ; Hunnicutt-Ferguson K; Stewart JW; McGrath PJ; Keller S; Peterson BS; Chen Y
J Affect Disord; 2017 Mar; 210():258-264. PubMed ID: 28064115
[TBL] [Abstract][Full Text] [Related]
34. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
36. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
37. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
40. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.
Perahia DG; Kajdasz DK; Royer MG; Walker DJ; Raskin J
Int Clin Psychopharmacol; 2006 Sep; 21(5):285-95. PubMed ID: 16877900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
